from the swamp (ihub) RedShoulder Member Level
Post# of 1460
(Total Views: 554)
Posted On: 02/16/2021 2:20:13 PM
from the swamp (ihub)
RedShoulder Member Level Tuesday, 02/16/21 11:52:51 AM
Re: None 0
Post #
299224
of 299241
New Paradigm in Alzheimer’s and its Etiology Finally Revealed. $SAVA $ATHA $AVXL.
Posted on February 14, 2021 by Piotr Pietrzkiewicz
If indeed the root cause of Alzheimer’s have been found then the implication for the field of Alzheimer’s drug studies and development are significant. First of all, it is the final death (!) of the plaque theory. This has beeen primary target for tens of years, but it seems that the root cause could only be elucidated with the knowledge of genetics and of cell differentaition during the fetal growth. The latter is of primary importance, I explain later why. Chromatin is brought into the picture here as the name of the therapeutic target but I suspect that the full insight can only be brought to shine once the mechanisms connected with the “bad” behavior of chromatin can be identified. Chromatin is only a cog in a larger mechanism.
I have been repeating that Blarcamesine (Anavex2-73) might be connected with some basic physiological mechanism involved in fetal development and aptly to my education (mechanical engineering) I called it “a quality control system” for protein synthesis in time of fetal development. Chromatin is here implicated. I also stressed the fact that the SIGMAR1 receptor seems to be most likely receptive to progesterone – the pregnancy hormone – since it is still unknown what serves as the natural agonist. In fetal development the single cell divides and differentiates into all the cells present in a newborn. This includes the CNS cells. The natural course of differentiation of cells and the ability to direct the transformations of cells into branches limiting the potential at every step has been a subject of research into so called stem cells therapies. At every step of the way a number of chemical signal with great effort has been curretly worked on. The are called growth factors. These growth factors stimulate the cells to go from one trasfomation into another. The far reaching promises is to cure old age frailty if not make us imortal. The promise is great like in any new field, so disappointments are also due, nevertheless this might be new reaserch area for therapetic compounds for degenerative disease of the CNS.
In cell biology a researcher can trigger a receptor and measure few biomarkers or compounds. Ultimately, he can monitor the health of a culture of cells due to a drug or agent. Much is obscured to the researcher, and much depends on his level of focus. Dr. Missling has never dealt extensively in biomarkers. Blarcamesine has been without any, at least approved by FDA, since it was a odd man out of the plaque paradigm. After phase 2a and its extension it became clear that Blarcamesine (Anavex2-73) might (cannot say yet “can”) rescue those who have not deteriorated below 20 points on MMSE scale, and have the right genetic make up, that is 80% of general population. The inklings is that SIGMAR1 agonist like Blarcamesine (Anvex2-73) is a drug working along the lines of the new pradigm. I start with the word of “inkling”, as I refrain form giving signs of full knowledge before the fullness of time . Efficacy of Blacamesine level has never been experienced in Alzheimer’s study. Yet, there is no direct evidence that Blarcamesine works 100% within the new paradigm so I stay true to form saying “inkling”. If we focus on the results with patients till now it seems we got the winner, wait for the results of Phase 2b/3. FDA has not allowed to select the patients on genetic markers, but the analysis after the adjustment might be very interesting. Up untill now, no study had shown that high Effect Size Cohen’s d like Blarcamesine. Pursuit of the plaque paradigm totaly absorbes the investsting public without exception for novel approaches.
The new pardigm talks of reversal in synoptic health. We can claim that Blarcamesine restores the synaptic health, and even acts as an enhancer of synaptic health as measured by amplitude of processing startling audible signal as the only biomarker available on Blarcamesine performance at this moment besides the improvement in cognitive scores in MMSE or ADCS-ADL .
In the light of the above article or rather discovery that the neurons of Alzheimer’s sufferes devolve, or lose thair ability to express genes neccesary to fulfil their fuction to create synapses and conduct the signal processing required of functioning neurons, Blarcamesine seems to be a drug theoretically and actually rescuing Alzheimer’s patients. Both the plaque in its amyloid and tau versions seems to be well down stream, and even the damage due to immflamuation seems to become a secondary aspect of the disease. In one great swoop a clear and logical etiology has been estblished for the disease. The reasons for the reversal of the function is yet unknown but instantly number of drugs either become totally obsolete or they become relegated to addressing symptoms and not the disease.
Great attention has been placed on the doubtful success of $SAVA, but I think that only has been because $SAVA therapeutically follows the line of plaque etilogy and as all these drugs has been more successful in “curing” the disease when one looks at biomarkers than actual patients. Of course, these biomarkers became now instantly obsolete, or rather secondary or even worse. Yet the pardigm of the plaque will die slowly and the new pardigm is certainly to deliver the final blow once it produces great disparity in trial results between the apporoches, too many careers are at stake as well as money.
https://piotrpeterblog.com/2021/02/14/new-par...atha-avxl/
InvestorsHub NewsWire
Featured This insanely Great Stock Market WILL Correct Soon These 5 Gold Stocks Deserve Your Attention Now! Feb 16, 2021 8:30 AM
Featured Emerging Growth Conference Scheduled for February 17, 2021 Niche Companies in Augmented Reality, Biotech, Cannabis and more... Feb 16, 2021 5:30 AM
Featured Manganese X Drill Program Intersects Wide Zones of Manganese Oxide Near Surface with a Program High of 27.69% Feb 16, 2021 3:19 AM
RedShoulder Member Level Tuesday, 02/16/21 11:52:51 AM
Re: None 0
Post #
299224
of 299241
New Paradigm in Alzheimer’s and its Etiology Finally Revealed. $SAVA $ATHA $AVXL.
Posted on February 14, 2021 by Piotr Pietrzkiewicz
If indeed the root cause of Alzheimer’s have been found then the implication for the field of Alzheimer’s drug studies and development are significant. First of all, it is the final death (!) of the plaque theory. This has beeen primary target for tens of years, but it seems that the root cause could only be elucidated with the knowledge of genetics and of cell differentaition during the fetal growth. The latter is of primary importance, I explain later why. Chromatin is brought into the picture here as the name of the therapeutic target but I suspect that the full insight can only be brought to shine once the mechanisms connected with the “bad” behavior of chromatin can be identified. Chromatin is only a cog in a larger mechanism.
I have been repeating that Blarcamesine (Anavex2-73) might be connected with some basic physiological mechanism involved in fetal development and aptly to my education (mechanical engineering) I called it “a quality control system” for protein synthesis in time of fetal development. Chromatin is here implicated. I also stressed the fact that the SIGMAR1 receptor seems to be most likely receptive to progesterone – the pregnancy hormone – since it is still unknown what serves as the natural agonist. In fetal development the single cell divides and differentiates into all the cells present in a newborn. This includes the CNS cells. The natural course of differentiation of cells and the ability to direct the transformations of cells into branches limiting the potential at every step has been a subject of research into so called stem cells therapies. At every step of the way a number of chemical signal with great effort has been curretly worked on. The are called growth factors. These growth factors stimulate the cells to go from one trasfomation into another. The far reaching promises is to cure old age frailty if not make us imortal. The promise is great like in any new field, so disappointments are also due, nevertheless this might be new reaserch area for therapetic compounds for degenerative disease of the CNS.
In cell biology a researcher can trigger a receptor and measure few biomarkers or compounds. Ultimately, he can monitor the health of a culture of cells due to a drug or agent. Much is obscured to the researcher, and much depends on his level of focus. Dr. Missling has never dealt extensively in biomarkers. Blarcamesine has been without any, at least approved by FDA, since it was a odd man out of the plaque paradigm. After phase 2a and its extension it became clear that Blarcamesine (Anavex2-73) might (cannot say yet “can”) rescue those who have not deteriorated below 20 points on MMSE scale, and have the right genetic make up, that is 80% of general population. The inklings is that SIGMAR1 agonist like Blarcamesine (Anvex2-73) is a drug working along the lines of the new pradigm. I start with the word of “inkling”, as I refrain form giving signs of full knowledge before the fullness of time . Efficacy of Blacamesine level has never been experienced in Alzheimer’s study. Yet, there is no direct evidence that Blarcamesine works 100% within the new paradigm so I stay true to form saying “inkling”. If we focus on the results with patients till now it seems we got the winner, wait for the results of Phase 2b/3. FDA has not allowed to select the patients on genetic markers, but the analysis after the adjustment might be very interesting. Up untill now, no study had shown that high Effect Size Cohen’s d like Blarcamesine. Pursuit of the plaque paradigm totaly absorbes the investsting public without exception for novel approaches.
The new pardigm talks of reversal in synoptic health. We can claim that Blarcamesine restores the synaptic health, and even acts as an enhancer of synaptic health as measured by amplitude of processing startling audible signal as the only biomarker available on Blarcamesine performance at this moment besides the improvement in cognitive scores in MMSE or ADCS-ADL .
In the light of the above article or rather discovery that the neurons of Alzheimer’s sufferes devolve, or lose thair ability to express genes neccesary to fulfil their fuction to create synapses and conduct the signal processing required of functioning neurons, Blarcamesine seems to be a drug theoretically and actually rescuing Alzheimer’s patients. Both the plaque in its amyloid and tau versions seems to be well down stream, and even the damage due to immflamuation seems to become a secondary aspect of the disease. In one great swoop a clear and logical etiology has been estblished for the disease. The reasons for the reversal of the function is yet unknown but instantly number of drugs either become totally obsolete or they become relegated to addressing symptoms and not the disease.
Great attention has been placed on the doubtful success of $SAVA, but I think that only has been because $SAVA therapeutically follows the line of plaque etilogy and as all these drugs has been more successful in “curing” the disease when one looks at biomarkers than actual patients. Of course, these biomarkers became now instantly obsolete, or rather secondary or even worse. Yet the pardigm of the plaque will die slowly and the new pardigm is certainly to deliver the final blow once it produces great disparity in trial results between the apporoches, too many careers are at stake as well as money.
https://piotrpeterblog.com/2021/02/14/new-par...atha-avxl/
InvestorsHub NewsWire
Featured This insanely Great Stock Market WILL Correct Soon These 5 Gold Stocks Deserve Your Attention Now! Feb 16, 2021 8:30 AM
Featured Emerging Growth Conference Scheduled for February 17, 2021 Niche Companies in Augmented Reality, Biotech, Cannabis and more... Feb 16, 2021 5:30 AM
Featured Manganese X Drill Program Intersects Wide Zones of Manganese Oxide Near Surface with a Program High of 27.69% Feb 16, 2021 3:19 AM
(2)
(0)Anavex Life Sciences Corp. (AVXL) Stock Research Links
Scroll down for more posts ▼